BACKGROUND: Infliximab (IFX) has been used for over a decade worldwide. Less is known about the natural history of IFX use beyond a few years and which @entity1 are more likely to sustain benefits. METHODS: @entity1 with @entity30 ( @entity30 ) exposed to IFX from Massachusetts General Hospital, Boston, Saint-Antoine Hospital, Paris, and the Swiss IBD Cohort Study were identified through retrospective and prospective data collection, complemented by chart abstraction of electronic medical records. We compared long-term users of IFX (>5 yr of treatment, long-term users of infliximab [LTUI]), with non-LTUI @entity1 to identify prognostic factors. RESULTS: We pooled data on 1014 @entity1 with @entity30 from 3 different databases, of whom 250 were defined as LTUI. The comparison group comprised 290 @entity1 with @entity30 who discontinued IFX: 48 primary nonresponses, 95 loss of responses, and 147 adverse events. Factors associated with LTUI were @entity1049 and an earlier age at the start of IFX. The prevalence of active smokers and @entity28 @entity1 differed markedly, but inversely, between American and European centers but did not impact outcome. The discontinuation rate was stable around 3% to 6%, each year from years 3 to 10. CONCLUSIONS: Young age at start of IFX and colonic @entity30 are factors associated with a beneficial long-term use of IFX. After 5 years of IFX, there is still a 3% to 5% discontinuation rate annually. Several factors associated with a good initial response such as nonsmoker and shorter disease duration at IFX initiation do not seem associated with a longer term response.

Factors associated with durable response to infliximab in XXXX 5 years and beyond: a multicenter international cohort.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"] @entity1049 :: ('MESH:D003108', 'Disease') :: ['colonic involvements']
@entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']
